Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

B.N. Hangalapura; D. Oosterhoff; T. Gupta; J. de Groot; P.G.J.T.B. Wijnands; V.W. van Beusechem; J. den Haan; T. Tuting; A.J.M. van den Eertwegh; D.T. Curiel; R.J. Scheper; T.D. de Gruijl

doi:10.1016/j.vaccine.2011.01.022

Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

B.N. Hangalapura
, D. Oosterhoff
, T. Gupta
, J. de Groot
, P.G.J.T.B. Wijnands
, V.W. van Beusechem
, J. den Haan
, T. Tuting
, A.J.M. van den Eertwegh
, D.T. Curiel
, R.J. Scheper
, T.D. de Gruijl

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	2313-2321
Journal	Vaccine
Volume	29
Issue number	12
DOIs	https://doi.org/10.1016/j.vaccine.2011.01.022
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.vaccine.2011.01.022

Cite this

Hangalapura, B. N., Oosterhoff, D., Gupta, T., de Groot, J., Wijnands, P. G. J. T. B., van Beusechem, V. W., den Haan, J., Tuting, T., van den Eertwegh, A. J. M., Curiel, D. T., Scheper, R. J., & de Gruijl, T. D. (2011). Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine, 29(12), 2313-2321. https://doi.org/10.1016/j.vaccine.2011.01.022

@article{d6832059a0b8462bbf2f7443e0535557,

title = "Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.",

author = "B.N. Hangalapura and D. Oosterhoff and T. Gupta and \{de Groot\}, J. and P.G.J.T.B. Wijnands and \{van Beusechem\}, V.W. and \{den Haan\}, J. and T. Tuting and \{van den Eertwegh\}, A.J.M. and D.T. Curiel and R.J. Scheper and \{de Gruijl\}, T.D.",

year = "2011",

doi = "10.1016/j.vaccine.2011.01.022",

language = "English",

volume = "29",

pages = "2313--2321",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "12",

}

Hangalapura, BN, Oosterhoff, D, Gupta, T, de Groot, J, Wijnands, PGJTB, van Beusechem, VW , den Haan, J, Tuting, T, van den Eertwegh, AJM, Curiel, DT, Scheper, RJ & de Gruijl, TD 2011, 'Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.', Vaccine, vol. 29, no. 12, pp. 2313-2321. https://doi.org/10.1016/j.vaccine.2011.01.022

TY - JOUR

T1 - Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

AU - Hangalapura, B.N.

AU - Oosterhoff, D.

AU - Gupta, T.

AU - de Groot, J.

AU - Wijnands, P.G.J.T.B.

AU - van Beusechem, V.W.

AU - den Haan, J.

AU - Tuting, T.

AU - van den Eertwegh, A.J.M.

AU - Curiel, D.T.

AU - Scheper, R.J.

AU - de Gruijl, T.D.

PY - 2011

Y1 - 2011

U2 - 10.1016/j.vaccine.2011.01.022

DO - 10.1016/j.vaccine.2011.01.022

M3 - Article

C2 - 21272606

SN - 0264-410X

VL - 29

SP - 2313

EP - 2321

JO - Vaccine

JF - Vaccine

IS - 12

ER -